{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-046380","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.794534+00:00","generated_at":"2026-05-15T04:54:33.945296+00:00","sec_items":["7.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rafael Holdings subsidiary Cyclo Therapeutics licenses MIT patent for cyclodextrins in ApoE4+ Alzheimer's","bullets":["Exclusive license covers U.S. Patent No. 12285440 for cyclodextrins in ApoE4-positive Alzheimer's patients.","ApoE4 variant present in 50-70% of Alzheimer's patients; Trappsol Cyclo targets cholesterol transport in CNS.","Phase 3 results for Transport NPC program due in calendar Q3 2026, per COO Joshua Fine.","CEO Howard Jonas calls the license a transformative milestone for the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-046380","json":"https://secwatch.observer/filing/0001213900-26-046380.json","markdown":"https://secwatch.observer/filing/0001213900-26-046380.md","text":"https://secwatch.observer/filing/0001213900-26-046380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000121390026046380/0001213900-26-046380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000121390026046380/ea0287258-8k_rafael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:54:33.945296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}